• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Hyperion DeFi Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    10/31/25 8:00:41 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HYPD alert in real time by email
    false 0001682639 0001682639 2025-10-27 2025-10-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): October 27, 2025

     

     

    HYPERION DEFI, INC.

    (Exact Name of Registrant as Specified in its Charter)

     

     

    Delaware   001-38365   47-1178401
    (State or other jurisdiction
    of incorporation)
      (Commission
    File Number)
      (IRS Employer
    Identification No.)

     

    23461 South Pointe Drive, Suite 390, Laguna Hills, CA 92653

    (Address of Principal Executive Offices, and Zip Code)

     

    (833) 393-6684

    Registrant’s Telephone Number, Including Area Code 

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    (Title of each class)   (Trading
    Symbol)
      (Name of each exchange
    on which registered)
    Common stock, par value $0.0001 per share   HYPD   The Nasdaq Stock Market
    (Nasdaq Capital Market)

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 1.01. Entry into a Material Definitive Agreement.

     

    On October 27, 2025, Hyperion DeFi, Inc. (“Hyperion” or the “Company”) entered into a Joint Validator Operators’ Agreement (the “Joint Validator Agreement”) with Kinetiq Research Pte. Ltd. (“Kinetiq Group”) and Pier Two Pty Ltd (“Pier Two”), effective retroactively to June 25, 2025. The Joint Validator Agreement formalizes the parties’ collaboration in jointly operating a co-branded validator node (“Kinetiq × Hyperion” or “KxH Node”) on the Hyperliquid Layer-1 blockchain (“Hyperliquid”).

     

    Under the Joint Validator Agreement, Hyperion initiated the validator with 10,000 HYPE and agreed to provide staking capital from its treasury of HYPE tokens, so that the validator enters Hyperliquid’s active set of validators and it is eligible to produce and attest blocks in the Hyperliquid consensus protocol. Kinetiq Group will contribute validator operations support, smart contract infrastructure, and stake-routing tooling via its liquid staking protocols, and Pier Two will host and manage the validator infrastructure, including uptime, monitoring and security, and will maintain ISO/IEC 27001 and SOC 2 compliance.

     

    The Joint Validator Agreement outlines shared responsibilities for validator operations, governance, incident response, and performance monitoring. It includes a revenue-sharing arrangement whereby staking commissions and other validator-level rewards are allocated among Hyperion, Kinetiq Group and Pier Two, with specific overrides for referred delegations. The Joint Validator Agreement also includes provisions for key management and quorum-based control of validator cryptographic material; service level obligations and remedies for performance shortfalls; and risk management and indemnification for slashing events or operational failures.

     

    The Joint Validator Agreement is effective for an initial term of one year and will automatically renew annually unless terminated by any party with 90 days’ notice. The agreement may also be terminated by any party for an event of default after a cure period; by any non-affected party if a force majeure event continues for more than a specified number of consecutive calendar days and materially impairs another party’s ability to carry out its obligations under the Joint Validator Agreement; and by Hyperion, at any time in its sole discretion, if the KxH Node remains unable to meet a specified active stake or falls out of the active set.

     

    The preceding description of the Joint Validator Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Joint Validator Agreement, which is expected to be filed as an exhibit to the Company’s next Annual Report on Form 10-K.

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    In addition, the previously announced resignation of Michael Rowe, the Company's former chief executive officer, will take effect on November 1, 2025.

     

    Item 7.01. Regulation FD Disclosure.

     

    On October 29, 2025, the Company issued a press release announcing entry into the HAUS Agreement (as defined below). A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

     

    The information in Item 7.01 of this Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

     

    Item 8.01. Other Events.

     

    On October 28, 2025, the Company entered into a Hype Asset Use Service Agreement (the “HAUS Agreement”) with Felix Foundation (“Felix”) to support the deployment of a perpetual futures market on the Hyperliquid protocol.

     

    Under the HAUS Agreement, Hyperion will allocate 500,000 HYPE tokens (the native token of Hyperliquid) to a multi-signature wallet controlled jointly by Hyperion and Felix. These tokens will be staked to satisfy the HIP-3 deployment requirements for launching a perpetual futures market (“HIP-3 Market”). Hyperion will retain full ownership of the allocated HYPE tokens, and Felix is prohibited from transferring, encumbering, or otherwise alienating the allocated HYPE tokens.

     

    Under the HAUS Agreement, which has an initial term of 52 weeks and is automatically renewable for successive 26-week periods unless terminated with 30 days’ notice, Hyperion will receive a share of HIP-3 Market revenues based on trading volume tiers, plus 100% of staking rewards.

     

     

     

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit
    Number
      Description
    99.1  Press Release, dated October 29, 2025.
    104  Cover Page Interactive Data File (embedded within the inline XBRL document).

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      HYPERION DEFI, INC.
       
    Date: October 31, 2025 /s/ Hyunsu Jung
      Hyunsu Jung
      Interim Chief Executive Officer

     

     

     

    Get the next $HYPD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HYPD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HYPD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hyperion DeFi Schedules Third Quarter 2025 Earnings Call for November 13, 2025

    LAGUNA HILLS, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ:HYPD) ("Hyperion DeFi" or the "Company"), the first U.S. publicly listed company dedicated to building a long-term strategic treasury of Hyperliquid's native token, HYPE, today announced that it will hold its earnings conference call and webcast for the third quarter ended September 30, 2025, on Thursday, November 13, 2025 at 5:00 p.m. Eastern Time. A press release detailing these results will be issued prior to the call on the same day. Participants may submit questions in advance of the call via email to [email protected]. A webcast of the call will be archived and available through Thursday, Novembe

    11/3/25 4:00:00 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hyperion DeFi Announces Strategic Partnership with Felix to Launch HIP-3 Powered Perpetual Futures Market

    LAGUNA HILLS, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ:HYPD) ("Hyperion DeFi" or the "Company"), the first U.S. publicly listed company dedicated to building a long-term strategic treasury of Hyperliquid's native token, HYPE, today announced a strategic partnership with HyperEVM protocol Felix ("Felix"), marking a significant milestone in decentralized finance innovation. Under the newly signed HYPE Asset Use Service (HAUS) agreement, Hyperion DeFi will provide the use of 500,000 HYPE to Felix, supporting the protocol's ability to launch and manage a custom on-chain perpetual futures market using Hyperliquid's revolutionary HIP-3 framework. HIP-3 (Hyperliquid

    10/29/25 8:00:00 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hyperion DeFi Announces Appointment of David Knox as Chief Financial Officer

    PayPal's Former Head of Capital Markets and Head of Finance for Global Credit and Financial Services Joins Company Strong Advocate for Blockchain Adoption for Traditional Institutional Financial Products LAGUNA HILLS, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) ("Hyperion DeFi" or the "Company"), the first U.S. publicly listed company building a long-term strategic treasury of Hyperliquid's native token, HYPE, today announced the appointment of David Knox, CFA, as Chief Financial Officer, effective immediately. This move is part of a broader strategic initiative to strengthen governance and accelerate the Company's decentralized finance ("DeFi") strateg

    9/29/25 8:00:00 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HYPD
    SEC Filings

    View All

    Hyperion DeFi Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - HYPERION DEFI, INC. (0001682639) (Filer)

    10/31/25 8:00:41 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Hyperion DeFi Inc.

    SCHEDULE 13G - HYPERION DEFI, INC. (0001682639) (Subject)

    10/22/25 8:11:07 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hyperion DeFi Inc. filed SEC Form 8-K: Leadership Update

    8-K - HYPERION DEFI, INC. (0001682639) (Filer)

    10/2/25 4:01:35 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HYPD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Knox David R. was granted 300,000 shares (SEC Form 4)

    4 - HYPERION DEFI, INC. (0001682639) (Issuer)

    10/1/25 4:02:32 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Knox David R.

    3 - HYPERION DEFI, INC. (0001682639) (Issuer)

    10/1/25 4:00:12 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Walters Happy David was granted 50,000 shares (SEC Form 4)

    4 - HYPERION DEFI, INC. (0001682639) (Issuer)

    9/9/25 4:08:07 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HYPD
    Leadership Updates

    Live Leadership Updates

    View All

    Hyperion DeFi Announces Appointment of David Knox as Chief Financial Officer

    PayPal's Former Head of Capital Markets and Head of Finance for Global Credit and Financial Services Joins Company Strong Advocate for Blockchain Adoption for Traditional Institutional Financial Products LAGUNA HILLS, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) ("Hyperion DeFi" or the "Company"), the first U.S. publicly listed company building a long-term strategic treasury of Hyperliquid's native token, HYPE, today announced the appointment of David Knox, CFA, as Chief Financial Officer, effective immediately. This move is part of a broader strategic initiative to strengthen governance and accelerate the Company's decentralized finance ("DeFi") strateg

    9/29/25 8:00:00 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HYPD
    Financials

    Live finance-specific insights

    View All

    Hyperion DeFi Schedules Third Quarter 2025 Earnings Call for November 13, 2025

    LAGUNA HILLS, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ:HYPD) ("Hyperion DeFi" or the "Company"), the first U.S. publicly listed company dedicated to building a long-term strategic treasury of Hyperliquid's native token, HYPE, today announced that it will hold its earnings conference call and webcast for the third quarter ended September 30, 2025, on Thursday, November 13, 2025 at 5:00 p.m. Eastern Time. A press release detailing these results will be issued prior to the call on the same day. Participants may submit questions in advance of the call via email to [email protected]. A webcast of the call will be archived and available through Thursday, Novembe

    11/3/25 4:00:00 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hyperion Defi to Report Second Quarter 2025 Results on Wednesday, August 13, 2025

    NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Hyperion Defi, Inc. (NASDAQ:HYPD), the first U.S. public company to build a strategic treasury around the HYPE token and a pioneer in integrating decentralized finance with traditional corporate treasury strategies, will host its second quarter 2025 earnings call on Wednesday, August 13, 2025, at 4:30 p.m. to review the financial and operating results. Participants should dial 1-877-407-9039 (domestic) or 1-201-689-8470 (international) with the conference code 13754799. A live webcast of the conference call will also be available here as well as on the investor relations page of the Company's corporate website at Hyperion Defi. To access the Ca

    8/8/25 4:05:00 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care